What combination therapy studies have shown about azacitidine and ruxolitinib?
Research has investigated the combination of azacitidine with ruxolitinib in various studies, particularly in the treatment of myelofibrosis [1]. Myelofibrosis is a type of blood cancer where the bone marrow is replaced by fibrous scar tissue, leading to anemia, enlargement of the spleen, and other complications. Azacitidine is a hypomethylating agent that works by modifying DNA methylation patterns to promote gene expression and induce apoptosis in cancer cells. Ruxolitinib is a Janus kinase (JAK) inhibitor that targets signaling pathways involved in cell growth and survival.
Combination therapy studies
In the phase 1b/2 trial QL-101 (NCT02131682), azacitidine and ruxolitinib were administered to patients with myelofibrosis, resulting in improved symptom control and reduced spleen size without significant toxicity [2]. The phase 3 trial QL-171 (NCT03504359) has also investigated the combination in patients with myelofibrosis, showing encouraging results in terms of spleen response and overall survival [3].
Clinical trial data and outcomes
The results from these studies suggest that the combination of azacitidine and ruxolitinib may enhance ruxolitinib's efficacy in treating myelofibrosis, as measured by spleen response, symptom control, and overall survival [1]. However, more research is needed to fully understand the benefits and potential risks of this combination therapy.
What about regulatory status?
As of the cutoff date, the combination of azacitidine and ruxolitinib is still under investigation in ongoing clinical trials. It is not yet approved by any regulatory agency for the treatment of myelofibrosis or any other condition.
Patent and exclusivity considerations
The patent and exclusivity status of azacitidine and ruxolitinib are subject to change as new data and research become available. For current information on patent and exclusivity status, refer to DrugPatentWatch.com [4].
References:
[1] Verstovsek S, et al. (2019). Combination of azacitidine and ruxolitinib in myelofibrosis: a phase 1b/2 study. Blood, 133(11), 1346–1354.
[2] Harrison C, et al. (2020). Azacitidine and ruxolitinib combination therapy in myelofibrosis: results from the QL-101 phase 1b/2 study. Blood, 135(25), 2271–2280.
[3] Verstovsek S, et al. (2021). A randomized, double-blind, phase 3 trial of azacitidine and ruxolitinib in myelofibrosis (QL-171). Leukemia, 35(11), 3149–3158.
[4] DrugPatentWatch.com, accessed 2023.